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Chapter 1 General Introduction 
 
1.1. Significance of G Protein–coupled Receptors (GPCRs) as Drug Targets. 
G protein–coupled receptors (GPCRs) constitute the largest family of membrane 
proteins and play pivotal roles in a diverse range of biological functions in living cells. 
There is a high proportion of drugs targeting GPCRs when comparing the number of 
launched and clinical drugs in terms of target protein class (Figure 1).
1
  
 
 
Figure 1. Top 10 target families of established and clinical trial drug targets. This figure 
is created by the data of Annu. Rev. Pharmacol. Toxicol. 2014, 54, 9-26. 
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It is quite obvious that there is a great importance to the drugs targeting GPCRs. 
There are nearly a thousand different GPCRs in the human genome and a lot of orphan 
GPCRs without a endogenous ligand are remained to be coded.
2
 However, novel 
endogenous ligands for more than 70 orphan GPCRs have been identified in recent 
world-wide studies (Figure 2).  
 
 
Figure 2. Ratio of GPCRs classified based on the GRAFS system. This figure is created 
by the data of Annu. Rev. Pharmacol. Toxicol. 2013, 53, 127-46. 
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1.2. Roles of Metastin and KISS1 Receptor. 
1.2.1. About Human Metastasis Suppressor Gene KISS1. 
Novel key genes expressed in both human placenta and malignant tumors have been 
identified and implicated in the modulation of tumor invasion and metastasis. In this 
regard, KISS1 has been identified as a human metastasis suppressor gene encoding a 
C-terminal amidated protein, metastin, that suppresses metastasis of human melanomas 
and breast carcinomas.
3-5
 
 
 
Figure 3. Hypothetical processing pathway of KISS-1 gene product including removal of 
the signal peptide and cleavage by a prohormone convertase and a carboxypeptidase. 
 
Metastin/kisspeptin was first isolated from human placenta and proposed to be the 
7
endogenous ligand of an orphan G-protein-coupled receptor KISS1R, also known as 
GPR54 or AXOR12, and recently renamed KISS1R that is expressed throughout the 
central nervous system and in a variety of endocrine and gonadal tissues.
3-5
  
 
Metastin, which is an amidated peptide with 54 amino acid residues, is encoded by 
the metastasis-suppressor (KISS1) gene, the mRNA of which is expressed in the human 
placenta and brain, as well as in rodents (Figure 3). Therefore, metastin was firstly 
thought to facilitate the suppression of metastasis. Actually, metastin activates KISS1R 
and inhibits chemotaxis, cell motility and growth, and metastasis of human KISS1R 
(hOT7T175)-transfected B16-BL6 melanomas in vivo.
3-8
 However, physiological 
function of metastin as the metastasis suppressor has not been well elucidated. 
 
1.2.2. Metastin as a Critical Regulator of Gonadotropin Releasing Hormone 
(GnRH) Secretion. 
More recently, fundamental studies have suggested that metastin acts as a critical 
regulator of gonadotropin releasing hormone (GnRH) secretion. Indeed, single 
administration of metastin potently induces follicle stimulating hormone (FSH)/ 
luteinizing hormone (LH) release in several mammalian species including rats (Figure 
4),
9
 mice,
10
 and human males.
11
 
Detailed observations revealed that KISS1 mRNA is expressed in the hypothalamic 
brain region,
10
 and KISS1R mRNA is expressed in hypothalamic GnRH neurons,
12
 
suggesting that metastin directly regulates GnRH release from GnRH neurons. The 
mutation of KISS1R gene was identified as a causative gene of idiopathic 
hypogonadotropic hypogonadism (IHH).
13
  
 
8
 Figure 4. The effect of metastin and cetrorelix on gonadotropin release in adult male 
Wistar rats (n = 5). Plasma LH levels in 10-week-old rats 90 min after subcutaneous 
administration of either metastin (100 nmol/kg) or saline, following pretreatment with 
cetrorelix (600 nmol/kg) or saline. Bars show means+SEM. ***P < 0:001 versus the 
other three groups by Tukey’s test. This data was published in Biochem Biophys Res 
Commun 2004, 320, 383-8. 
 
1.2.3. Phenotype of KISS1R Knockout Mice. 
Furthermore, KISS1R knockout mice showed a phenotype similar to human IHH.
14-15
 
The hypothalamic–pituitary–gonadal (HPG) axis is well known to regulate reproduction 
in all vertebrates by controlling the uterine and ovarian cycles; these findings indicated 
that metastin functions in the HPG axis (Figure 5). Taking this opportunity, 
physiological roles of metastin and KISS1R received a lot of attention in the field of 
neuroendocrinology. 
 
 
 
 
9
  
Figure 5. Schematic illustration demonstrating HPG axis, which regulate reproduction 
in all vertebrates. 
 
1.2.4. Hypothalamic–Pituitary–Gonadal (HPG) Axis. 
Hypothalamic hormones are synthesized by neurons in the hypothalamus and 
secreted into hypophyseal portal system to regulate the synthesis and release of anterior 
pituitary hormones. Hypothalamic hormones are divided into two classes, pituitary 
hormone releasing hormones and inhibitory hormones. More than ten hypothalamic 
hormones are thought to exist; six of them are identified by chemical structures and 
physiological roles. GnRH is one of hypothalamic hormones and composed of ten 
amino acids which stimulate the synthesis and release of LH and FSH (Figure 5). 
Gonadotropins are controlled by GnRH via a G protein-coupled receptor that activates 
phospholipase C transmiting its signal to diacylglycerol (DAG) and inositol 
10
1,4,5-trisphosphate (IP3). The gonadotropins stimulate the gonads, ovary, and testis, for 
follicular growth, ovulation, luteinization and sperm formation. Furthermore, the 
gonadotropins produce the sex steroids, estrogens and androgens, respectively. 
 
1.2.5. Pharmaceutical Target. 
Thus, drugs regulating the secretion of the gonadotropins have been thought to have 
therapeutic potentials for prevention or treatment of sex hormone dependent diseases, 
such as prostate cancer, gynecological disorder, infertility. There have been tremendous 
research and development activities in the past decades to discover that continuous 
administration of GnRH agonist induces downregulation and desensitization of GnRH 
receptor in the pituitary, which causes the suppression of gonadotropin release and the 
decrease in testosterone levels. By use of the findings, GnRH agonists such as 
leuprolide are widely used clinically for the treatment of hormone-dependent prostate 
cancer, breast cancer, endometriosis, uterine fibroid and precocious puberty. On the 
other hand, GnRH antagonists have been developed for the avoidance of the initial 
increase in gonadotropin release and gonadal hormone secretion after dosing of GnRH 
agonists, so-called "flare up" with this medication. 
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1.3. Active Site of Endogenous Ligand Metastin. 
Initial research revealed that the N-terminal truncated human metastin(45-54), 
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, not only has the complete biological 
activity of the full metastin protein but is 3 to 10 times more active than metastin 
(Figure 6).
3
  
 
 
 
Figure 6. Structures and biological activities of metastin and metastin(45-54) described 
in Nature 2001, 411, 613-617. 
 
Although short-length analogues of metastin have the potential of research tool for 
the elucidation of metastin and KISS1R functions and possess therapeutic properties, 
their susceptibility to enzyme cleavage limits their utility.
16
 Generally, peptides are 
degraded by proteases in serum, especially short-length peptides show rapid enzymatic 
degradation. 
12
1.4. Aims of This Study. 
The previous results showing the proposed function of metastin at the upper stream of 
GnRH suggest that appropriate dosing of KISS1R agonists can manipulate the 
hypothalamic-pituitary-gonadal axis with the potential to assist in the prevention or 
treatment of a number of sex hormone-dependent diseases. 
 
In this study biological stability of metastin(45-54) was planned to evaluate for the 
rational synthetic strategy to give enhanced biological stability of short-length KISS1R 
agonists with the maintenance of potent agonist activities. One of the aims of this 
research was to obtain tool peptides capable of working in vivo to elucidate 
physiological functions of metastin and KISS1R (Figure 7). 
 
 
 
Figure 7. Aims of this study about design and synthesis of short-length KISS1R agonist. 
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Tool peptides were thought to be designed and synthesized using appropriate amino 
acid substitutions and amide bond isosteres to maintain KISS1R agonist activity and 
avoid degradation by proteases. Target profiles of tool peptides were set in terms of 
molecular weight, KISS1R affinity, KISS1R agonist activity, biological stability and 
water solubility. Molecular weight with less than one-fifth of metastin (54 amino acids), 
KISS1R affinity with more potent than metastin, KISS1R agonist activity with more 
potent than metastin, biological stability with more than 50% residual rate in rodent 
serum for 60 min at 37°C and water solubility with more than 1 mM were supposed to 
be needed for tool peptides working in vivo. 
 
Moreover, the other aim of this research was to establish general strategy for the drug 
discovery and development targeting orphan GPCRs by using biologically stable 
peptide analogue. Biologically stable peptide was thought to be a powerful tool to 
elucidate functions of orphan GPCRs with peptide ligands. 
 
This thesis presents rational strategies to give novel KISS1R agonists and a new 
insight into drug discovery and development targeting orphan GPCRs with peptide 
ligands.   
14
Chapter 2 Trypsin Resistance of a Decapeptide KISS1R Agonist Containing an 
N
ω
-Methylarginine Substitution 
 
2.1. Summary of Chapter 2. 
Metastin/kisspeptin is an amidated peptide with 54 amino acid residues; compared to 
the full-length metastin, the N-terminal truncated peptide metastin(45-54) has 3–10 
times higher receptor affinity and enhanced ability to increase intracellular calcium 
concentration which is essential for activation of protein kinases involved in 
intracellular signaling in a number of pathways that affect reproduction and cell 
migration. However, metastin(45-54) is rapidly inactivated in serum. In this chapter, we 
designed and synthesized a number of metastin(45-54) analogues and evaluated their 
agonist activity and trypsin resistance. Among analogues with substitutions of arginine 
at position 53, N
ω
-methylarginine (Arg(Me)) analogue 8 showed 3-fold more potent 
agonist activity compared with metastin(45-54). Furthermore, analogue 8 was shown to 
resist trypsin cleavage between positions 53 and 54. This substitution may be useful in 
the development of other Arg-containing peptides for which the avoidance of cleavage 
is desired. 
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2.2. Background and Strategy. 
Native metastin consists of 54 amino acid residues. However, the N-terminal 
truncated human metastin(45-54), Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, 
not only has the complete biological activity of the full metastin protein but is 3 to 10 
times more active than metastin.
3
 Although short-length analogues of metastin have the 
potential to possess therapeutic properties, their susceptibility to enzyme cleavage is 
thought to limit their utility.
16
 Biological stability of metastin(45-54) has not been 
investigated in detail and the cleavage sites by serum proteases have not been well 
elucidated. In this chapter biological stability of metastin(45-54) was planned to 
evaluate for the rational synthetic strategy to give enhanced biological stability of 
short-length KISS1R agonists with the maintenance of potent agonist activities. 
Cleavage sites of metastin(45-54) by proteases were planned to identify by LC/MS/MS 
methodology after the treatment of mouse plasma. Subsequent amino acid substitutions 
and/or incorporation of amide bond isosteres at cleavage sites were thought to be 
resistant to serum proteases. All analogues were designed as ten-amino-acid peptides 
and evaluated in terms of KISS1R agonist activity, followed by the selection of potent 
analogues for the further investigation of biological stability using biological fluid or 
protease. 
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2.3. Determination of Biological Stability of Metastin(45-54). 
First, the biological stability of short-length peptide metastin(45-54) was 
investigated; metastin(45-54) was rapidly metabolized in mouse plasma, and more than 
50% of the peptide was metabolized after a 1-min incubation at 37°C (Figure 8). 
 
 
Figure 8. HPLC chromatogram of metastin(45-54) after incubation in mouse plasma. 
 
The metabolites formed during the incubation in serum were identified by 
high-performance liquid chromatography/electrospray ionization mass spectrometry 
(HPLC-ESI-MS) coupling experiments using an ESI ion trap mass spectrometer (LCQ, 
Thermo-Fisher) (Figure 9). 
 
 
 
 
 
17
 Figure 9. Schematic diagram to analyze digested peptides of metastin(45-54) by 
HPLC-ESI-MS coupling experiments. 
 
ESI mass spectra obtained from metastin(45-54) incubated with mouse plasma 
revealed the presence of more than ten plausible metabolites (Figure 10). Two major 
peptide fragments, metastin(46-54) and (46-53), were released primarily as a result of 
Tyr
45
-Asn
46
 and Arg
53
-Phe
54
 protease cleavage due to aminopeptidase activity and 
trypsin-like degradation. 
 
 
 
 
 
 
18
 Figure 10. Total ion chromatogram of metastin(45-54) after incubation in mouse plasma. 
 
Arg-containing peptides are known to be good substrates for trypsin-like proteases.
17–
19
 Therefore, we designed and synthesized a series of short-length KISS1R agonists to 
examine their agonist activity and trypsin resistance. We used an isolated bovine trypsin 
to evaluate the stability of these potential agonists against trypsin degradation. In this 
chapter, we focus on the Arg
53
-Phe
54 
cleavage and describe a rational and unique 
strategy for the design of KISS1R agonists resistant to trypsin-like proteases (Figure 
11). 
19
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2.4. Design and Synthesis of Metastin(45-54) Analogues Substituted at Position 53. 
2.4.1. Chemistry. 
All peptides were synthesized by standard fluorenylmethyloxycarbonyl (Fmoc)-based 
solid phase synthetic methodology (Scheme 1). Crude peptides were purified to 
homogeneity by preparative HPLC and purity was ascertained by analytical HPLC; 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was 
performed to assign the structure. 
 
2.4.2. Biological Activities. 
The synthesized analogues were characterized by an intracellular calcium ion 
mobilization assay of KISS1R (hOT7T175) using fluorometric imaging plate reader 
(FLIPR) technology. The ability to increase intracellular calcium ion levels ([Ca
2+
]i 
activity) of all peptides is shown in Table 1 as the EC50 values (nM) and the specific 
activity relative to metastin(45-54); higher EC50 ratios indicate lower activity compared 
to metastin(45-54). 
 
2.4.3. Substitution with Neutral Amino Acids. 
Metastin contains an RF-amide C-terminal structure. The Arg residue in position 53 
of metastin(45-54) plays an important role in its biological activity. Metastin analogues 
in which Arg is substituted with neutral L-amino acids such as alanine (Ala) 1, leucine 
(Leu) 2, norleucine (Nle) 3, and citrulline (Cit) 4, which are expected to prevent trypsin 
recognition and degradation, also showed a 21-112-fold reduction in agonist activities 
(Figure 12, Table 1) demonstrating that the presence of a basic amino acid at the 
position 53 is necessary for the biological activity of metastin(45-54).
21
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Substitution for Arg
53
 with Lys decreased its binding affinity for KISS1R by 
10-fold.
20
 In our study using the FLIPR assay Lys
53
 analogue 5 exhibited 4.2-fold 
decreased agonist activity compared to metastin(45-54) (Table 1). 
 
Table 1. Structures and biological activities of metastin(45-54) analogues substituted at 
position 53. 
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-AA53-Phe-NH2 
  agonist activitya 
compound AA53 EC50 (nM) EC50 ratiob 
metastin(45-54) Arg 0.065c 1.0 
1 Ala 1.4 21 
2 Leu 1.5 23 
3 Nle 5.8 89 
4 Cit 7.2 110 
5 Lys 0.27 4.2 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R 
(hOT7T175), an intracellular calcium mobilization assay using FLIPR technology.  
bEC50 ratio is the ratio of each peptide EC50 value compared with the EC50 value of metastin(45-54). 
cEC50 value of metastin(45-54) is calculated as the average value of 14 independent experiments. 
 
 
Figure 12. Structures of amino acids at position 53.
23
2.4.4. Substitution with D-Amino Acid. 
It has been widely recognized that substitution of an L-amino acid with the 
corresponding D-amino acid sometimes provides peptides with improved biological 
potency because it alters conformational properties of the peptide
21
 and increases 
resistance to enzymatic degradation.
22
 However, substitution of Arg
53
 with D-Arg in 
metastin(45-54) markedly decreased its agonist activity for KISS1R
15
. In our studies, 
the agonist activity of [D-Arg
53
]metastin(45-54) 6 was lower than that of 
metastin(45-54) by more than three orders of magnitude (Figure 13, Table 2). 
 
 
Figure 13. Structures of amino acids at position 53. 
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Table 2. Structures and biological activities of metastin(45-54) analogues substituted at 
position 53. 
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-AA53-Phe-NH2 
  agonist activitya 
compound AA53 EC50 (nM) EC50 ratiob 
metastin(45-54) Arg 0.065c 1.0 
6 D-Arg 76 1200 
7 Om 0.29 4.5 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R 
(hOT7T175), an intracellular calcium mobilization assay using FLIPR technology.  
bEC50 ratio is the ratio of each peptide EC50 value compared with the EC50 value of metastin(45-54). 
cEC50 value of metastin(45-54) is calculated as the average value of 14 independent experiments. 
 
2.4.5. Trypsin and Substitution with Ornithine. 
Trypsin is known to exhibit a relatively low activity for ornithyl substrates,
23
 and it is 
anticipated that the substitution of Arg would increase the stability of the bond between 
the residues 53 and 54. However, the replacement of Arg with ornithine (Orn) yielded 
analogue 7 which had 4.5-fold lower agonist activity (Figure 13, Table 2). 
 
2.4.6. Substitution with Guanidino-N-Alkyl (N
ω
-Alkyl) Arginine. 
Since guanidino-N-alkyl (N
ω
-alkyl) arginine derivatives, which retain the positive 
charge of Arg, exhibit different lipophilicity and electrostatic characteristics, we 
originally examined whether the substitution of N
ω
-alkyl arginine derivatives was 
effective in the improvement of the in vivo agonist potential and serum stability of our 
analogues. Metastin(45-54) analogues with N
ω
-alkyl arginine 8-12 were synthesized, 
and their [Ca
2+
]i-mobilizing activities were compared with that of metastin(45-54) 
(Figure 14). 
 
Because homoarginine (Har) and norarginine (Nar) derivatives have been shown to 
be resistant to tryptic degradation,
24
 we synthesized metastin(45-54) analogues with 
25
substituted Har 13 and Nar 15 and their N
ω
-methylated derivatives 14 and 16 (Figure 
14). 
 
 
Figure 14. Structures of amino acids at position 53. 
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Guanylation was performed with 1H-pyrazole-1-carboxamidine hydrochloride as the 
transferable amidine moiety, and methylguanylation was successfully performed using 
N-methyl-N,N′-bis-Boc-1-guanylpyrazole prepared by methylation of commercially 
available N,N′-bis-Boc-1-guanylpyrazole.25 
 
In analogues with guanidino moieties, side chain elongation may result in improved 
receptor interaction. N
ω
-Methylarginine (Arg(Me)) 8, N
ω,ω
-dimethylarginine 
(Arg(Me2)asy) 9, N
ω
-ethylarginine (Arg(Et)) 11, Har 13, and N
ω
-methylhomoarginine 
(Har(Me)) 14 analogues retained their high agonist activities with EC50 ratios below 2.1. 
Analogues 8 and 9 possessed higher [Ca
2+
]i mobilization activity compared with 
metastin(45-54) (Table 3). 
 
Table 3. Structures and biological activities of metastin(45-54) analogues substituted at 
position 53. 
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-AA53-Phe-NH2 
  agonist activitya 
compound AA53 EC50 (nM) EC50 ratiob 
metastin(45-54) Arg 0.065c 1.0 
8 Arg(Me) 0.023 0.36 
9 Arg(Me2)asy 0.039 0.61 
10 Arg(Me2)sym 0.32 4.9 
11 Arg(Et) 0.065 1.0 
12 Arg(Pr) 0.36 5.6 
13 Har 0.029 0.45 
14 Har(Me) 0.13 2.1 
15 Nar 0.15 2.3 
16 Nar(Me) 0.34 5,2 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R 
(hOT7T175), an intracellular calcium mobilization assay using FLIPR technology.  
bEC50 ratio is the ratio of each peptide EC50 value compared with the EC50 value of metastin(45-54). 
cEC50 value of metastin(45-54) is calculated as the average value of 14 independent experiments. 
 
The N
ω
-propylarginine (Arg(Pr)) derivative 12, with a relatively large substituent 
27
group at the guanidino moiety, reduced biological activity by more than 5.6-fold 
compared to the Arg(Et) derivative 11. These data suggest that KISS1R can recognize 
metastin(45-54) with limited modifications at position 53. 
 
2.4.7. Substitution with Other Basic Amino Acids. 
In addition to these analogues containing the guanidino moiety at the side chain of 
position 53, we introduced N
ε,ε
-dimethyllysine (Lys(Me2)) 17; 2,4-diaminobutanoic acid 
(Dbu) 18; 2,3-diaminopropionic acid (Dpr) 19; N

-glycyldiaminopropionic acid 
(Dpr(Gly)) 20; and N

-(N-amidinoglycyl)diaminopropionic acid (Dpr(AmGly)) 21 
substitutions at position 53 to investigate the relationship between the structures of the 
basic side chains and agonist activity (Figure 15). 
 
 
Figure 15. Structures of amino acids at position 53. 
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Although Lys(Me)2 analogue 17 had the highest agonist activity among the analogues 
containing unnatural amino acids without guanidino moieties at position 53, its EC50 
value was 5.1-fold higher than that of metastin(45-54) (Table 4). Two analogues with 
short side chains, 18 and 19, showed markedly lower agonist activities than Orn 
analogue 7. These results indicated that KISS1R recognized not only the structure of the 
basic moiety but also the distance between the main chain and a particular basic moiety. 
 
Table 4. Structures and biological activities of metastin(45-54) analogues substituted at 
position 53. 
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-AA53-Phe-NH2 
  agonist activitya 
compound AA53 EC50 (nM) EC50 ratiob 
metastin(45-54) Arg 0.065c 1.0 
17 Lys(Me)2 0.33 5.1 
18 Dbu 3.9 61 
19 Dpr 1.4 21 
20 Dpr(Gly) 10 160 
21 Dpr(AmGly) 2.2 34 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R 
(hOT7T175), an intracellular calcium mobilization assay using FLIPR technology.  
bEC50 ratio is the ratio of each peptide EC50 value compared with the EC50 value of metastin(45-54). 
cEC50 value of metastin(45-54) is calculated as the average value of 14 independent experiments. 
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2.5. Trypsin Resistance of Metastin(45-54) and its Analogues. 
Based on these results, we examined the effect of trypsin degradation on these 
N-terminal truncated human metastin analogues, namely, metastin(45-54), Lys analogue 
5, and Arg(Me) analogue 8. After 30-min incubation of 0.1 mM peptide with bovine 
trypsin ((E/S=1/100 (W/W)) in ammonium acetate buffer at pH 8.5, metastin(45-54) 
and [Lys
53
]metastin(45-54) 5 were rapidly degraded but Arg(Me) analogue 8 remained 
intact (Figure 16). 
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2.6. Serum Stability of Metastin(45-54) and its Analogues. 
2.6.1. Stability and Metabolites. 
To investigate its metabolic stability in biological fluids, we incubated [Arg(Me)
53
] 
metastin(45-54) 8 in 0.1 mM in mouse serum for 5 min. The digest was characterized 
by LCMS using ion trap mass spectrometry (Figure 17). Although enzymatic 
degradation of analogue 8 in mouse serum yielded several peptide fragments, none were 
due to cleavage between positions 53 and 54 demonstrating that this Arg(Me) 
substitution improved serum stability by preventing cleavage between positions 53 and 
54. Peak X in the figure was observed as an unknown substance derived from serum 
protein.  
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2.6.2. Rate of Degradation. 
Kinetic data on the degradation of these compounds in mouse serum are shown in 
Figure 18. Metastin(45-54) or analogue 8 (5 μL of 1 mM aqueous solution) was 
incubated with 45-μL of mouse serum at 37°C for up to 10 min. At 1, 2, 5, and 10 min, 
the incubations were stopped by boiling for 3 min. The amount of peptide in serum 
extracts was determined from the area under HPLC peaks. The percent of a given 
KISS1R agonist recovered from serum after incubation at 37°C (stability index) was 
calculated relative to the amount of peptide extracted from serum at time 0. 
 
  
Figure 18. Stability of metastin(45-54) and [Arg(Me)53]metastin(45-54) 8 in mouse blood 
samples (HPLC analysis). 
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Rate constants for disappearance and half-life were calculated according to 
pseudo-first-order kinetic models and optimized using monoexponential regressions. 
The calculated half-lives of the metastin(45-54) and analogue 8 were 0.56 and 1.8 min, 
respectively, demonstrating that replacement of Arg by Arg(Me) improved stability of 
analogue 8 in mouse serum. Other analogues including Har 13, Har(Me) 14, and Nar 15 
were stable after treatment with trypsin (data not shown). 
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2.7. Conclusion of Chapter 2 
Methylation of the guanidino group of Arg was first recognized more than 40 years 
ago as a result of post-translational modifications of Arg residues.
26
 Our study of 
metastin(45-54) analogues demonstrated improved peptide stability by substituting Arg 
residue with Arg(Me). Trypsin-like proteases have been reported to cleave the 
C-terminal end of basic amino acids such as Arg or Lys.
11
 However, this is the first 
report showing that the replacement of Arg by Arg(Me) is a promising approach to 
prevent the cleavage of an Arg-containing peptide by trypsin-like proteases. In 
conclusion, the improvement in metabolic stability by Arg(Me) substitution may be 
useful in the development of other peptide derivatives of metastin(45-54) with higher 
agonist activity. 
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Chapter 3 Serum Stability of Selected Decapeptide Agonists of KISS1R Using 
Pseudopeptides 
 
3.1. Summary of Chapter 3 
Metastin, a 54-amino acid peptide, is the ligand of the G protein-coupled receptor 
KISS1R; the N-terminally truncated decapeptide, metastin(45-54), has 3–10 times 
higher receptor affinity and intracellular calcium ion-mobilizing activity but is rapidly 
inactivated in serum. In this study we designed and synthesized stable KISS1R agonist 
decapeptide analogues with selected substitutions at positions 47, 50, and 51. 
Replacement of glycine with azaglycine (azaGly) in which the α-carbon is replaced with 
a nitrogen atom at position 51 improved the stability of amide bonds between 
Phe
50
-Gly
51
 and Gly
51
-Leu
52
 as determined by in vitro mouse serum stability studies. 
Substitution for tryptophan at position 47 with other amino acids such as serine, 
threonine, -(3-pyridyl)alanine, and D-tryptophan (D-Trp), produced analogues that 
were highly stable in mouse serum. D-Trp
47
 analogue 34 showed not only high 
metabolic stability but also excellent KISS1R agonist activity. Other labile peptides may 
have increased serum stability using amino acid substitution. 
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3.2. Background and Strategy. 
N-Terminally truncated human metastin(45-54), Tyr-Asn-Trp-Asn-Ser-Phe-Gly- 
Leu-Arg-Phe-NH2, is 3–10 times more active than metastin in vitro.
3
 However, both 
metastin and metastin(45-54) are susceptible to enzyme-catalyzed hydrolysis.
16
 As 
mentioned in the previous chapter, metastin(45-54) was rapidly metabolized in mouse 
plasma. More than 50% of the peptide was metabolized after a 1-min incubation at 37°C. 
The metabolites formed during incubation were identified by HPLC-ESI-MS coupling 
experiments. ESI mass spectra obtained from metastin(45-54) incubated with mouse 
plasma revealed the presence of more than ten plausible metabolites. Two major peptide 
fragments, metastin(46-54) and (46-53), were released primarily as a result of 
Tyr
45
-Asn
46
 and Arg
53
-Phe
54
 protease cleavage due to aminopeptidase activity and 
trypsin-like degradation. We determined that Arg(Me) substitution at the 53 position 
was an optimal approach to improve serum stability by avoiding cleavage between 
Arg
53
 and Phe
54
 (Figure 19). 
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 Figure 19. Cleavage sites of metastin(45-54) and compound 8 with improved serum 
stability. 
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N
ω
-Methylarginine [Arg(Me)] substitution has been shown to be highly effective in 
preventing the cleavage between amino acids Arg
53
 and Phe
54
. Consequently, an 
analogue possessing Arg(Me) was synthesized and found to be metabolically resistant to 
trypsin-like proteases. 
 
There remains a great demand for more stable analogues with other amino acid 
replacements at fragile sites to improve their pharmacological properties by maintaining 
or improving agonist activity and serum stability. In this chapter, a rational strategy is 
provided for the design of decapeptide analogues of KISS1R agonists to improve their 
stability in murine serum by focusing on the replacement of cleavage sites. All 
analogues were designed as ten-amino-acid peptides and evaluated in terms of KISS1R 
agonist activity, followed by the selection of potent analogues for the further 
investigation of biological stability using biological fluid. 
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3.3. Design and Synthesis of Metastin(45-54) Analogues Substituted between 
Positions 50 and 51. 
3.3.1. Substitution with D-Tyrosine (D-Tyr) at Position 45. 
Incorporation of D-amino acids has been widely recognized to improve biological 
potencies of peptides by altering conformational properties
21
 and increasing resistance 
to enzymatic degradation.
22
 Peptide 22 with D-Tyr
45
 showed acceptable activity and 
avoided N-terminal degradation (Figure 20, Table 5). 
 
 
Figure 20. Structures of amino acids at position 45.
41
Table 5. Biological activities of metastin analogues substituted at position 45. 
H-AA45-Asn-Trp-Asn-Ser-Phe-Gly-Leu-AA53-Phe-NH2 
   
agonist 
activitya 
 stability in mouse 
serum 
compound AA45 AA53 EC50 (nM)  residual ratio (%)c 
metastin(45-54) Tyr Arg 0.049b  NDd 
8 Tyr Arg(Me) 0.023  NDd 
22 D-Tyr Arg(Me) 0.065  18.1 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R (hOT7T175), an 
intracellular calcium mobilization assay using FLIPR technology. EC50 values of all peptide analogues were 
calculated using sigmoidal dose response curves. bEC50 values of metastin(45-54) were calculated as the 
average value of 13 independent experiments. cResidual ratio after incubation in mouse serum for 1 hr at 
37°C. dNot determined. 
 
Mouse plasma stability experiments showed that peptide 22 was apparently resistant 
to proteolysis after a 1 h incubation in mouse serum and showed a treated/control (T/C) 
ratio of 18.1%, even though several metabolites were observed in the ESI-MS spectra 
including metastin(45-47), (45-50), (45-51), and (48-54), possibly due to cleavage by 
chymotrypsin-like proteases, neutral endopeptidases (NEP), and matrix 
metalloproteinase-9 (MMP-9), as shown in Figure 21. Peak X in the figure was 
observed as an unknown substance derived from serum protein.
42
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3.3.2. Substitution with D-Amino Acid or N-Methyl Amino Acid at Positions 50 and 
51. 
We hypothesized that more potent and long-acting analogues of compound 22 could 
be developed if other degradative pathways were successfully inhibited by specific 
replacement at positions 47, 48, 50, and 51. To examine this hypothesis, we first 
synthesized a series of analogues with substitution of residues at positions 50 and 51. 
Preliminary data (not shown) suggested that amino acid substitutions at Phe
50
 and Gly
51
 
preserved receptor recognition. D-Amino acid or N-methyl amino acid replacement 
improved metabolic stability but reduced in vitro activity. 
 
3.3.3. Substitutions with Dipeptide Isosteres between Positions 50 and 51. 
Therefore, we designed and synthesized amide bond isosteres and aza amino acid 
additions between positions 50 and 51 without altering their side chain moieties (Figure 
22). This was expected to improve agonist activity and avoid enzymatic degradation by 
changing the overall conformation of compound 22.
44
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Pseudopeptides have become important for medicinal chemistry.
27
 A previous study 
demonstrated that Gly-Leu dipeptide isosteres, such as (E)-alkene- and 
hydroxyethylene-type isosteres, helped to maintain the agonist activity against 
MMP-9-mediated cleavage.
27
 Metastin analogues with five amino acid residues 
containing (E)-alkene and hydroxyethylene isosteres showed high stability in murine 
serum.
16
 
 
In this chapter, we designed and synthesized other simple pseudopeptides including 
thio peptides, reduced amide peptides, retro-inverso peptides and aza peptides (Figure 
23). 
 
 
Figure 23. Structures of dipeptide isosteres at positions 50 and 51.
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3.3.4. Chemistry, Biological Activities and Serum Stability. 
All peptides were synthesized by standard Fmoc-based solid phase synthetic 
methodology except where specifically described (Scheme 2). The [Ca
2+
]i-mobilizing 
activities of all peptides are shown as the concentration at 50% of the maximum 
response (EC50 values) calculated using sigmoidal dose response curves in Tables 6, 7 
and 8. The receptor binding affinities of the synthesized peptides were determined as 
IC50 values. 
 
The ability of selected peptides to prevent enzymatic hydrolysis was evaluated by 
incubation in mouse serum at 37°C. The residual ratio, defined as the percent of 
compound remaining after a 1 h incubation at initial concentrations of 0.1 mM, is given 
in Tables 6, 7 and 8. 
 
3.3.5. Synthesis Peptides with Dipeptide Isosteres. 
Modification of peptides by reduction or thiolation of amide carbonyl oxygen has 
received attention recently for several reasons. For example, thiolated analogues of 
biologically active peptides have been reported to show increased enzymatic stability, 
potency, and selectivity.
28,29
 Thiolation of Fmoc-Phe-Gly-OtBu was achieved by means 
of Lawesson's reagent in toluene at 80 C for 2 hours, followed by TFA treatment to 
obtain Fmoc-Pheψ(CSNH)Gly-OH. 
 
The reduced amide bond (CH2NH) in compound 24 was formed by reductive 
alkylation of a preformed Fmoc-Phe-H with H-Leu-Arg(Me,Boc2)-Phe-Rink amide 
MBHA resin in the presence of an excess NaBH3CN and 1% acetic acid in 
N,N-dimethylformamide (DMF).
30-32
47
 Scheme 2.  Synthetic route to compounds 22-26 
48
Pseudopeptide 25 was synthesized by solid phase synthesis of retro-inverso 
peptides.
33
 The amide functional group of Z-Phe-NH2 was converted into an amine with 
bis(trifluoroacetoxy)iodobenzene, followed by condensation with 
mono-tert-butylmalonate and subsequent conversion of the Z group into an Fmoc group. 
Deprotection of tert-butyl ester by TFA treatment for 3 min afforded the desired 
pseudodipeptide, Fmoc-Phe-ψ(NHCO)-Gly-OH, which was used for the solid phase 
peptide synthesis. 
 
Aza peptides have an aza amino acid residue in which the α-carbon is replaced with a 
nitrogen atom. This nitrogen substitution is believed to have little effect on the overall 
physicochemical profiles of these peptides; however, electronic repulsion between the 
lone pairs of the adjacent nitrogen atoms of hydrazine moiety has been suggested to 
induce type I and II β-turn conformations.34-46 
 
This β-turn geometry of aza amino acid-containing peptides may contribute to 
improve binding affinity of metastin analogues for KISS1R. NMR analysis of the 
metastin(45-54) analogue in dodecylphosphocholine micelles showed that it contained 
several tight turn structures such as miscellaneous type IV β-turns (residues Asn48–Gly51 
and Gly
51–Phe54).47 In addition, this manipulation is expected to increase the stability of 
the aza peptide against proteases that recognize amino acid residues Phe
50–Gly51 or 
Gly
51–Leu52 due to the planar configuration of α-nitrogen between D- and L-amino acids. 
We designed an aza peptide and synthesized it using solid phase methodology. 
 
3.3.6. Biological Activities of Peptides with Dipeptide Isosteres. 
All of these analogues including thio peptide 23, reduced amide peptide 24, 
49
retro-inverso peptide 25, and aza peptide 26, retained acceptable [Ca
2+
]I mobilizing 
activities and receptor binding activities (Table 6). Stability against enzymatic 
hydrolysis was evaluated in mouse serum and the amount of peptide remaining in serum 
extracts was determined from the area under HPLC peaks. The stability index defined as 
the percent of a given metastin analogue recovered from serum after incubation at 37°C 
for 1 h, was calculated relative to the amount of peptide at time 0 (Table 6). 
 
Thio peptide 23, retro-inverso peptide 25, and aza peptide 26 displayed increased 
stability in mouse serum; however, reduced amide peptide 24 exhibited a lower residual 
ratio compared with peptide 1. It was assumed that retro-inverso peptide and aza peptide 
analogues could avoid cleavage of amide bonds between the residues 50 and 51 and 51 
and 52. The azaGly analogue was selected for further optimization studies because of its 
superior water solubility and synthetic characteristics.
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3.4. Design and Synthesis of Metastin(45-54) Analogues Substituted at Position 47. 
3.4.1. Substitution with Unnatural and Hydrophilic Amino Acids at Position 47. 
The sequence containing tryptophan at position 47 was prone to enzymatic 
degradation by chymotrypsin-like proteases which are known to exhibit high affinity for 
aromatic amino acid substrates such as phenylalanine, tyrosine, and tryptophan.
48,49
 On 
the other hand, it was expected that these chymotrypsin-like proteases would exert a 
relatively low activity against substrates that had unnatural or hydrophilic amino acids.  
 
 
Figure 25. Structures of amino acids at position 47.
53
Based on this, the following modifications were carried out to increase the stability of 
the bond between residues 47 and 48 (Figure 24, 25). 
 
3.4.2. Substitution with Serine at Position 47. 
Replacement of Trp
47
 with serine (Ser) yielded analogue 27 with relatively low 
bioactivity but superior metabolic stability compared with compound 26 (Table 7). The 
residual ratio of compound 27 after a 1 h incubation was 50.0%. 
 
Table 7. Biological activities of decapeptide metastin analogues substituted at position 
47. 
H-D-Tyr-Asn-AA47-Asn-Ser-Phe-azaGly-Leu-Arg(Me)-Phe-NH2 
  
agonist 
activitya 
 binding affinityb 
IC50 (nM) 
 stability in mouse serum 
compound AA47 EC50 (nM)  human rat  residual ratio (%)c 
26 Trp 0.050  0.16 0.17  39.5 
27 Ser 0.73  0.49 0.43  50.0 
aAgonist activities of all peptide analogues were evaluated in a functional assay of KISS1R (hOT7T175), an 
intracellular calcium mobilization assay using FLIPR technology. EC50 values of all peptide analogues were 
calculated using sigmoidal dose response curves. bReceptor binding affinities of the synthesized peptides were 
determined as IC50 values. cResidual ratio after incubation in mouse serum for 1 hr at 37°C. 
 
Several metabolites were identified by HPLC-ESI-MS coupling experiments 
following a 1 h incubation of compound 27 which was a prototype model peptide with 
an azaGly residue (Figure 26). Peak X in the figure was also observed as an unknown 
substance derived from serum protein. Compound 27 was not cleaved between positions 
50 and 52, and resisted proteolytic degradation in a 15 min human serum incubation in 
which metastin(45-54) showed rapid decomposition (Table 8).
54
 Figure 26. Total ion chromatogram of compound 27 after incubation in mouse 
serum. 
 
Table 8. Stabilities of metastin analogues in human serum. 
 residual ratio
a  
compound 0 min 5 min 10 min 15 min t1/2
b 
(min) 
metastin(45-54) 66 0.9 <0.5 <0.5 <1 
22 93.4 90.7 85.8 82.7 75 
27 86.5 86.5 85.3 86.4 stable 
aResidual ratio was determined after incubation in human serum 1 hr at 37°C (n=2). bThe half-lives of 
studied analogues were calculated according to pseudo-first-order kinetic models and optimized using 
monoexponential regressions. 
 
 
3.4.3. Substitution with a Variety of Amino Acids at Position 47. 
KISS1R recognition has been reported to be relatively unaffected by the structure of 
the N-terminal region of metastin(45-54). D-Amino acid substitutions at positions 45, 46, 
and 47 in metastin(45-54) retained potent biological activity comparable to 
metastin(45-54),
50,51
 suggesting that optimization at residue 47 with L- or D-amino acids 
55
would result in novel analogues with both high [Ca
2+
]i mobilizing activities and serum 
stability. 
 
AzaGly
51
 derivatives substituted with unnatural amino acids for Trp
47
, 
-cyclohexylalanine (Cha) 30, -(4-pyridyl)alanine [Pya(4)] 32, and 
-(2-naphthyl)alanine [Nal(2)] 33 analogues demonstrated comparable 
[Ca
2+
]i-mobilizing activities compared with Trp analogue 26 (Table 9). Of these 
analogues, Nal(2) analogue 33 showed the highest activity and was nearly equivalent to 
that of metastin(45-54). However, the residual ratios of these compounds was less than 
50%. 
 
Table 9. Biological activities of decapeptide metastin analogues substituted at position 
47. 
 
H-D-Tyr-Asn-AA47-Asn-Ser-Phe-azaGly-Leu-Arg(Me)-Phe-NH2 
  
agonist 
activitya 
binding affinityb 
IC50 (nM) 
 stability in mouse serum 
compound AA47 EC50 (nM) human rat  residual ratio (%)c 
26 Trp 0.050 0.16 0.17  39.5 
27 Ser 0.73 0.49 0.43  50.0 
28 Thr 0.24 0.86 0.83  62.5 
29 Ile 0.13 0.43 0.46  NDd 
30 Cha 0.10 0.19 0.24  32.0 
31 Pya(3) 0.24 0.70 0.89  50.6 
32 Pya(4) 0.11 0.30 0.28  30.7 
33 Nal(2) 0.098 0.13 0.20  43.6 
34 D-Trp 0.072 0.19 0.22  56.4 
35 D-Pya(4) 0.59 0.28 0.28  NDd 
aAgonist activities of all peptide analogues were evaluated in a functional assay KISS1R (hOT7T175), an 
intracellular calcium mobilization assay using FLIPR technology. EC50 values of all peptide analogues were 
calculated using sigmoidal dose response curves. bReceptor binding affinities of the synthesized peptides were 
determined as IC50 values. cResidual ratio after incubation in mouse serum for 1 hr at 37°C. dNot determined. 
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Other L-amino acid substitutions such as threonine (Thr) 28, isoleucine (Ile) 29, and 
-(3-pyridyl)alanine [Pya(3)] 31, showed decreased agonist activities compared to 
metastin(45-54), although the residual ratios of peptides 28 and 31 were above 50% in 
serum stability studies. 
 
As for D-amino acid substitutions, D-Trp
47
 34 and D-Pya(4)
47
 35 analogues exhibited 
good receptor binding affinity, which were comparable to the corresponding L-form 
amino acid derivatives 26 and 32. This result suggested that the stereochemistry of the 
α-carbon at position 47 does not play a critical role in KISS1R recognition, as expected. 
In addition, D-Trp analogue 34 showed excellent serum stability with a residual ratio of 
56.4%, compared to 39.5% for Trp analogue 26.
57
3.5. Conclusion of Chapter 3. 
In summary, we designed and synthesized metabolically stable KISS1R decapeptides 
with selected substitutions at positions 47, 50, and 51. Replacement of Gly with an 
azaGly residue, which involved a simple nitrogen atom replacement of an α-carbon at 
Gly, resulted in good agonist activity for KISS1R. This indicated that some β-turn 
conformations, which are reported to be observed in aza peptides, may contribute to 
interactions with KISS1R. Additionally, incorporation of the azaGly
51
 residue improved 
metabolic stability of the Phe
50
-Gly
51
 and Gly
51
-Leu
52 
bonds, which were resistant to 
serum proteases such as chymotrypsin, NEP, and MMP-9. Although a variety of aza 
amino acid analogues of biologically active peptides has been reported with improved 
biological potency,
52-63
 this study is the first report that aza amino acid replacement is a 
simple way to protect both fragile amide bonds at the N-terminal and C-terminal of the 
aza amino acid residue. 
 
Substitution of Trp at position 47 with other amino acids, exemplified in this series of 
analogues with azaGly
51
, produced several analogues that were stable to metabolic 
degradation. Our study demonstrated that the key amino acid replacement with azaGly
51
 
resulted in metabolically stable analogues that could be easily synthesized using 
solid-phase methodology without preparing dipeptide isostere units. Further 
optimization studies on novel azaGly short length metastin agonists with high potency 
and metabolic stability are described in the next chapter.
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Chapter 4 Design, Synthesis, and Biological Evaluation of Novel Investigational 
Nonapeptide KISS1R Agonists with Testosterone-suppressive Activity 
 
4.1. Summary of Chapter 4. 
Metastin is a 54 amino acid peptide ligand of the KISS1R receptor and is a critical 
regulator of GnRH secretion. The N-terminally truncated peptide, metastin(45-54), 
possesses 10-fold higher receptor-binding affinity and agonist KISS1R activity but is 
rapidly inactivated in rodent plasma. We have developed a decapeptide analogue 
[D-Tyr
45
,D-Trp
47
,azaGly
51
,Arg(Me)
53
]metastin(45-54) 34, with improved serum stability 
compared with metastin(45-54), but decreased KISS1R agonist activity. Amino acid 
replacements at positions 45-47 led to enhancement of KISS1R agonist activity and 
metabolic stability. N-terminal truncation resulted in a stable nonapeptide, 
[D-Tyr
46
,D-Pya(4)
47
,azaGly
51
,Arg(Me)
53
]metastin(46-54), compound 56, which 
displayed KISS1R binding affinities comparable to metastin(45-54) and had improved 
serum stability. 
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Compound 56 reduced plasma testosterone in male rats and is the first short-length 
metastin analogue to possess testosterone suppressive activities. Compound 56 has led 
to the elucidation of investigational analogues TAK-683 and TAK-448, both of which 
have undergone clinical evaluation for hormone-dependent diseases such as prostate 
cancer. 
60
4.2. Background and Strategy. 
Native metastin contains 54 peptide residues, but an N-terminally truncated analogue 
metastin(45-54) displays full biological activities in vitro. This fragment peptide is 
three- to ten-fold more active than native metastin,
3
 indicating that the active core of 
biological activity resides in the C-terminal region of metastin. 
 
Peptides are often not regarded as promising drug candidates because peptide bonds 
can be enzymatically fragile frequently resulting in rapid degradation by various serum 
proteases. Modifications of peptides can sometimes increase metabolic stability and 
improve their potential therapeutic utility. 
 
In the previous chapters, rational modifications of metastin(45-54) lead to the 
development of [D-Tyr
45
,Arg(Me)
53
]metastin(45-54) 22, which had greater metabolic 
stability than metastin(45-54). Both D-tyrosine (D-Tyr) at position 45 and 
N
ω
-methylarginine [Arg(Me)] at position 53 substitutions were acceptable and 
maintained KISS1R activity while avoiding N-terminal and C-terminal degradations, 
respectively. Metabolic stability was further improved by azaGly substitution at position 
51. Replacement of Gly by an azaGly residue improved stability for the 50-51 and 
51-52 bonds, which was expected to confer resistance to serum proteases such as 
chymotrypsin, NEP, and MMP-9. Substitution of Trp in position 47 with Ser or D-Trp 
also improved metabolic stability. 
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Building on these earlier investigations, the aim of the present study was to create 
metastin analogues with improved resistance to serum proteases while maintaining a 
high metastin agonist activity compared with our lead compound 34 (Figure 27). All 
analogues were designed as decapeptides or nonapeptides, and evaluated in terms of 
KISS1R agonist activity and binding affinity, followed by the selection of potent 
analogues for the further investigation of biological stability using biological fluid. 
Moreover, biological investigation in vitro and in vivo of selected compounds was 
planned for the elucidation of roles of metastin and KISS1R. 
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4.3. Design and Synthesis of KISS1R Agonists Substituted between Positions 45 
and 47. 
4.3.1. Substitution with Pya(4), D-Trp, D-Pya(4) at Position 47. 
Based on the study described in the previous chapter
 
of decapeptide metastin(45-54) 
analogues, azaGly
51
 was shown to be a key structure for good agonist activity and 
enzymatic stability in mouse serum. Analogues with an azaGly
51
 moiety avoided 
cleavage by proteases at positions 50-51 and 51-52. In further optimization studies 
performed here, azaGly
51
 derivatives which substituted for Trp
47
 with D-Trp
47
 34 and 
D-Pya(4)
47
 35, which were expected to avoid enzymatic degradation, had calcium 
mobilization activity comparable to corresponding L-amino acid derivatives 26 and 32 
(Table 10). These results implied that the stereochemical configuration of the side chain 
at position 47 did not play a critical role in receptor recognition. A wide variety of 
substitutions were predicted to be tolerated between residues D-Tyr
45
 and Trp
47
. 
Combination of amino acid substitutions/deletions between positions 45 and 47 was 
thought to show improved biological activity and stability of metastin analogues 
(Figure 27).
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4.3.2. Chemistry. 
All peptides were synthesized by a standard Fmoc-based solid phase synthetic 
method (Scheme 3). Obtained crude peptides were purified to homogeneity with 
preparative HPLC. The purity of each peptide was ascertained by analytical HPLC, and 
the structure assignment was performed by MALDI-TOF MS. 
 
4.3.3. Biological Activities. 
Synthesized analogues were characterized in two assays for human KISS1R activity. 
The first was an intracellular calcium mobilization assay using FLIPR technology and 
the second was a binding assay. The calcium mobilization assay used CHO cells stably 
expressing recombinant human KISS1R and the binding assay used the membrane 
fraction of human KISS1R-expressing cells. The maximum response observed in the 
presence of a given compound was corrected for the baseline measurement and 
expressed as a percent of the corrected response to a maximal concentration of control 
metastin(45-54). Nonlinear regression of normalized data was performed to estimate the 
potencies (EC50) of all compounds. 
 
4.3.4. Serum Stability. 
The stability against enzymatic hydrolysis of selected peptides was evaluated in 
mouse serum after incubation at 37
 
°C. The stability index of synthetic metastin 
derivatives was determined as the percent of compound remaining after 1 h incubation 
at an initial concentration of 0.1 mM.
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 Scheme 3.  General synthetic route to compounds 36-58 
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4.3.5. Decapeptide Analogues Substituted between Positions 45 and 47. 
Decapeptide analogues with amino acid substitutions between positions 45 and 47 
were designed and synthesized to obtain analogues showing improved biological 
activity and stability (Figure 28, 29, 30, 31). 
 
 
Figure 28. Structures of amino acids at position 46. 
 
D-Amino acid substitutions were also expected to improve the pharmacokinetic 
profiles of metastin derivatives. In our previous studies, KISS1R recognition was shown 
to be unaffected by the structure of the N-terminal region of metastin(45-54), even if 
D-amino acid substitutions were made between positions 45 and 47. D-Asn
46
 derivative 
37 exhibited nearly the same [Ca
2+
]i mobilizing activity as that of the L-form analogue 
26, and showed more potent agonist activity than other derivatives with hydrophilic 
amino acids such as D-Ser 38 and D-His 39 (Figure 28, Table 11). 
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Analogues of 37 were synthesized that substituted Cha 41, Thr 42, Pya(4) 43, and 
D-Trp 44 for Trp
47
; these were acceptable amino acids for Asn
46
 derivatives (Figure 29, 
Table 11). A Phe
47
 analogue 40, which was expected to show improved serum stability 
due to a D-amino acid at the adjacent position, was also prepared. 
 
 
Figure 29. Structures of amino acids at position 47. 
 
Analogue 40 possessed comparable in vitro agonist activity to metastin(45-54), 
however, the serum stability was decreased compared with that of Asn
46
-Trp
47
 analogue 
26. Although Thr
47
 analogue 42 showed excellent serum stability with a residual ratio of 
65.8%, the agonist activity as well as the binding affinity was reduced. Cha and D-Trp 
analogues 41 and 44 also exhibited decreased [Ca
2+
]i mobilizing activities. However, as 
Pya(4) analogue 43 showed excellent [Ca
2+
]i mobilizing activity and receptor-binding 
affinities, compound 43 was selected as a candidate for the human KISS1R transfected 
69
CHO (CHO/h175) cell growth inhibitory test described below. 
 
Replacement of D-Tyr
45
 with other amino acids including D-Ala 45, D-Pya(3) 46, 47, 
and Tyr 48 resulted in moderate agonist activities that were not superior to the series of 
D-Tyr analogues (Figure 30, 31, Table 11). 
 
 
Figure 30. Structures of amino acids at position 45. 
70
 Figure 31. Structures of amino acids at positions 45 and 47. 
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4.4. Design and Synthesis of Nonapeptide KISS1R Agonists Substituted at 
Positions 46 and 47. 
4.4.1. Deamidation of Asn-containing Peptide. 
Asn-containing peptides have been shown to undergo spontaneous rearrangement 
(i.e., Asn conversion to Asp and β-Asp) in aqueous environments (Figure 32).64-65 
Therefore, deletion of Asn at position 46 was intended to avoid inactivation of the 
peptide through chemical isomerization.  
 
 
Figure 32. Proposed scheme of deamidation reaction of an Asn-containing metastin 
analogue 26 in aqueous solution.
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The biological activities of the synthesized nonapeptides are summarized in Table 12 
and 13. The Asn
46
-deleted analogue 49 exhibited a slight increase in binding affinity 
compared with decapeptide analogue 26. The phenol group of Tyr
45
 was thought to be 
important for receptor recognition, but not to play a pivotal role (Table 12). 
 
 
Figure 33. Structures of amino acids at position 47. 
 
4.4.2. Nonapeptide Analogues Substituted at Positions 46 and 47.  
D-Amino acid substitutions between positions 45 and 47 in metastin(45-54) were 
75
acceptable for maintenance of the in vitro activities of decapeptides 26, 34, 37, and 48. 
Positions 45-47 were considered to be flexible for receptor recognition. This was 
supported by data showing that modifications at the Tyr
45
-Trp
47
 positions 51-58 of the 
nonapeptide analogues resulted in small decreases in biological activity (Figure 33, 34). 
 
 
Figure 34. Structures of amino acids at positions 46 and 47. 
 
Nonapeptide analogues which substituted for Trp
47
 with Thr 51, Ile 52, Phe 53, and 
Nal(2) 54 had three- to six-fold lower agonist activity than Trp analogue 19 (Table 13). 
On the other hand, D-amino acid substitutions at the Trp
47
 position, such as D-Trp 55 
and D-Pya(4) analogue 56, did not hamper the potent agonist activities. D-Pya(4) 
analogue 56 displayed good agonist activity in vitro and high binding affinity to the 
receptor, which was similar to that of metastin(45-54).
76
Ta
bl
e 
13
. B
io
lo
gi
ca
l a
ct
iv
ity
 o
f n
on
ap
ep
tid
e 
m
et
as
tin
 a
na
lo
gu
es
. 
H
-A
A4
6 -
AA
47
-A
sn
-S
er
-P
he
-a
za
G
ly
-L
eu
-A
rg
(M
e)
-P
he
-N
H
2 
 
 
 
 
 
 
 
ag
on
is
t 
ac
tiv
ity
a 
EC
50
 
ra
tio
 
 
 
af
fin
iti
es
 K
i n
M
 (9
5%
 C
I)b
 
 
st
ab
ilit
y 
in
 m
ou
se
 
se
ru
m
 
 
 
co
m
po
un
d 
AA
46
 
AA
47
 
 
 
hu
m
an
 
 
 
hu
m
an
 
ra
t 
 
 r
es
id
ua
l r
at
io
 (%
)c
 
 
4
9
 
D
-T
yr
 
Tr
p 
 
2.
4 
  
 
 
0.
04
4 
(0
.0
37
-0
.0
52
) 
0.
05
9 
(0
.0
45
-0
.0
76
) 
 
43
.4
  
 
5
0
 
D
-T
yr
 
Se
r 
 
61
  
  
  
 
 
0.
21
 (0
.1
5-
0.
31
) 
0.
30
 (0
.2
2-
0.
40
) 
 
N
D
d  
 
5
1
 
D
-T
yr
 
Th
r 
 
8.
9 
  
 
 
0.
20
 (0
.1
6-
0.
25
) 
0.
24
 (0
.1
8-
0.
32
) 
 
N
D
d  
 
5
2
 
D
-T
yr
 
Ile
 
 
14
  
  
  
 
 
0.
12
 (0
.0
90
-0
.1
7)
 
0.
13
 (0
.0
89
-0
.1
9)
 
 
N
D
d  
 
5
3
 
D
-T
yr
 
Ph
e 
 
7.
7 
  
 
 
0.
08
6 
(0
.0
62
-0
.1
2)
 
0.
15
 (0
.1
1-
0.
23
) 
 
N
D
d  
 
5
4
 
D
-T
yr
 
N
al
(2
) 
 
6.
4 
  
 
 
0.
03
2 
(0
.0
27
-0
.0
38
) 
0.
05
1 
(0
.0
43
-0
.0
61
) 
 
N
D
d  
 
5
5
 
D
-T
yr
 
D
-T
rp
 
 
4.
5 
  
 
 
0.
06
5 
(0
.0
57
-0
.0
75
) 
0.
11
 (0
.0
72
-0
.1
6)
 
 
N
D
d  
 
5
6
 
D
-T
yr
 
D
-P
ya
(4
) 
 
4.
8 
  
 
 
0.
08
9 
(0
.0
72
-0
.1
1)
 
0.
10
 (0
.0
74
-0
.1
4)
 
 
54
.9
  
 
5
7
 
D
-P
ya
(3
) 
Ph
e 
 
5.
8 
  
 
 
0.
20
 (0
.1
6-
0.
24
) 
0.
28
 (0
.2
1-
0.
38
) 
 
N
D
d  
 
 5
8
 
D
-P
ya
(3
) 
Tr
p 
 
 8
.7
  
  
 
 0
.1
1 
(0
.0
67
-0
.1
8)
 
0.
13
 (0
.0
75
-0
.2
3)
 
 
 
N
D
d  
a  E
C
50
 v
al
ue
s 
of
 [C
a2
+ ] 
in
cr
ea
si
ng
 a
ct
iv
iti
es
 o
f a
ll 
pe
pt
id
e 
an
al
og
ue
s 
w
er
e 
ev
al
ua
te
d 
as
 ra
tio
s 
to
 th
at
 o
f m
et
as
tin
(4
5-
54
). 
b 
C
on
ce
nt
ra
tio
n 
re
qu
ire
d 
to
 in
hi
bi
t s
pe
ci
fic
 b
in
di
ng
 b
y 
50
%
. c
 R
es
id
ua
l r
at
io
 a
fte
r i
nc
ub
at
io
n 
in
 m
ou
se
 s
er
um
 a
t 3
7 
°C
 w
as
 e
va
lu
at
ed
. d
 N
ot
 d
et
er
m
in
ed
. 
77
Furthermore, this D-amino acid substitution improved the serum stability of 
compound 56, as indicated by the residual ratio of 54.9% in mouse serum at 37
 
°C. 
Compound 56 with good water solubility of 1 mM met the criteria initially set as tool 
peptide which was expected to work in vivo.  
 
Replacement of D-Tyr
46
 with D-Pya(3) in analogues 57 and 58 introduced a 
hydrophilic/aromatic side chain for improvement of stability and solubility and retained 
moderate agonist activities, although no improvement over the series of D-Tyr 
analogues was observed. Consequently, substitution of N-terminal Tyr/D-Tyr residues in 
decapeptide and nonapeptide metastin analogues was determined to be the best choice, 
although further investigations employing other aromatic amino acid substitutions may 
provide even better results. 
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4.5. Effect of Metastin Analogues on the Growth of KISS1R Transfected CHO 
Cells.  
We previously reported that metastin inhibited human KISS1R transfected CHO 
(CHO/h175) cell growth and colony formation.
66
 To examine the ability of metastin 
analogues to inhibit KISS1R-mediated cell growth, we compared the inhibitory activity 
of compounds 22, 26, 32, 43, and 56 on CHO/h175 cell proliferation. Metastin 
significantly inhibited growth of CHO/h175 cells in liquid culture (IC50 = 21.2 nM) and 
inhibited colony formation in semi-solid agarose at a concentration of 5 μM. 
 
Table 14. Inhibition of CHO/h175 cell growth by metastin and metastin analogues. 
compound IC
50
 (nM)
a
 
 
metastin   21.2 
 
metastin(45-54) 8510 
 
22   87.0 
 
26    9.67 
 
32   18.3 
 
43   41.2 
 
56    8.94 
a
 IC50 values of cell growth inhibitory activity in hOT7T175-expressed 
CHO cells cultured in Dulbecco's Modified Eagle's medium (DMEM) 
with 10% dialyzed fetal bovine serum (FBS). 
 
The N-terminally truncated analogue metastin(45-54) showed inhibitory activity 
against CHO/h175 cell growth, however, the IC50 value was decreased (IC50 = 8510 
nM) compared with native metastin (Table 14). But the metastin analogues had greatly 
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improved antiproliferative activity compared with metastin(45-54). The lead compound 
with D-Tyr
45
 and Arg(Me)
53 
22 slowed cell growth in CHO/h175 cells with an IC50 of 
87.0 nM, which suggested that the functional activity and the biological stability of 
compound 22 were improved by several key amino acid substitutions. Substitutions at 
positions 47 and 51 revealed that azaGly analogues with Trp
47
 26 and Pya(4)
47
 32 
showed further improvements in growth inhibitory activities together with enhancement 
of serum stability. The IC50 values of peptides 26 and 32 were 9.67 and 18.3 nM, 
respectively, which is up to 40-times more potent than metastin(45-54). 
 
 
Figure 35. Inhibition of CHO/h175 cell growth by metastin and compound 56. 
 
Among the series of decapeptide metastin analogues, D-Asn
46
-Pya(4)
47
 derivative 43 
was tested because it showed the lowest EC50 ratio. However, the IC50 value of growth 
inhibitory activity was not improved (IC50 = 41.2 nM) compared with 26 and 32. This 
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might be due to the lower metabolic stability of compound 43 compared with those of 
the Asn
46
 derivatives 26 and 32. 
 
Similar to the decapeptide analogues, the representative nonapeptide analogue 56 
inhibited cell growth in CHO/h175 cells with an IC50 of 8.94 nM (Table 14, Figure 35). 
We believe that several key amino acid substitutions in compound 56 play an important 
role in the improved functional activity and enzymatic stability. 
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4.6. Ovulation Induction Activity in Immature Female Wistar Rats. 
The first in vivo pharmacodynamic experiment was carried out to obtain 
proof-of-concept using an ovulation induction model in immature female Wistar rats
9
 
that were primed with equine chorionic gonadotropin (eCG, 10 IU/rat). A single 
subcutaneous dose of human CG (hCG; 10 IU/rat), which was used as a positive 
control, was sufficient to trigger ovulation in all of the animals (n = 5), with a mean of 
26.0 oöcytes per animal. The number of oöcytes obtained is shown in Figure 36 and the 
minimum effective dose of metastin was 100 nmol/kg. 
 
 
Figure 36. Induction of ovulation in immature rats by metastin and compound 56 
compared to saline and hCG (10 IU/rat)
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When compound 56 was administered at 30 or 100 nmol/kg, the average number of 
oöcytes was 31.4 or 29.2, respectively, which indicated that the efficacy of compound 
56 was essentially equivalent to that of hCG. In summary, a short-length peptide 56 
showed ovulation induction activity in vivo comparable to full-length metastin, 
confirming proof-of-concept. 
 
By comparison, metastin(45-54), a short-length peptide that has strong agonist 
activity, did not show ovulation induction activity compared with compound 56 (Figure 
37). This suggests that in vivo efficacy of compound 56 is based not only on good 
agonist activity, but also on biologic stability.  
 
 
 
 
Figure 37. Induction of ovulation in immature rats by metastin(45-54) and compound 56 
at a dose of 100 nmol/kg compared to saline and hCG (10 IU/rat)
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4.7. Efficacy of KISS1R Agonists for Decreasing Testosterone Levels in Intact Male 
Rats. 
As previously reported,
67,68
 the continuous administration of metastin or 
metastin(45-54) to normal male rats temporarily increased their testosterone levels 
followed by a subsequent decrease to below normal levels. Our lead compound 22 and 
the optimized peptide 56 with nine amino acid residues including azaGly
51 
were 
subjected to an intact male rat assay. In this assay, plasma testosterone levels were 
determined at steady state after 6 days of continuous administration of each metastin 
analogue. These results provided a direct measure of the in vivo efficacy of compounds 
22 and 56 in the suppression of testosterone levels in an intact animal model using male 
Crl:CD(SD) rats (Figure 38). 
 
 
 
 
Figure 38. Plasma testosterone suppression in intact male rats by decapeptide 
compound 22 and optimal nonapeptide 56 at a dose of 2 nmol/hr compared to a distilled 
water (DW) control. 
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The limit of plasma testosterone measurement in this RIA was 0.04 ng/mL; values 
below 0.04 ng/mL were estimated as 0.04. As shown in Figure 38, compound 56 
suppressed testosterone levels lower than the limit of detection (0.04 ng/mL), 
demonstrating that compound 56 was more effective at lowering testosterone levels than 
compound 22. 
 
In a second experiment using male Copenhagen rats (Figure 39), both 2 nmol/h 
administration of compound 56 and 6 nmol/h administration of metastin attenuated 
plasma testosterone levels. 
 
 
Figure 39. Plasma testosterone suppression by continuous administration of compound 
56 or metastin in male rats at doses of 2 or 6 nmol/h, respectively compared to a 
distilled water (DW) control. 
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The plasma concentrations of the short-length peptide 56 (2 nmol/h) and metastin (6 
nmol/h) in this study were 0.95 and 4.07 nM, respectively. The in vivo efficacy of 
compound 56 might be based on its enzymatic stability in plasma. In addition, the 
moderate bioavailability (40.4 ± 4.9%) of compound 56 after subcutaneous 
administration at 1 mg/kg in IGS/SD rats might be explained by resistance to enzymatic 
degradation in subcutaneous tissue. 
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4.8. Continuous Administration of Compound 56 and Leuprolide Acetate in Male 
Rats for 13 Days. 
Compound 56 and leuprolide acetate
69
 were administered to male rats to compare 
plasma testosterone reducing efficacy. Plasma testosterone levels were determined after 
6 and 13 days of continuous administration. 
 
Continuous administration of compound 56 and leuprolide acetate at a dose of 1 
nmol/h for 13 days significantly suppressed testosterone in all rats (Figure 40). The 
plasma testosterone levels in rats receiving compound 56 decreased faster than in those 
receiving leuprolide acetate. Six-day dosing of compound 56 dramatically reduced 
plasma testosterone levels in rats; two of five rats showed plasma testosterone 
concentrations below the limit of detection (0.04 ng/mL). These findings suggest that 
the mechanisms of action for reducing plasma testosterone are different between 
metastin and GnRH agonists. 
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4.9. Conclusion of Chapter 4. 
In order to identify metastin analogues with improved metabolic stability and 
enhanced potency in vivo, a series of metastin(45-54) analogues containing three key 
replacements – N-terminal D-Tyr residue, azaGly51, and Arg(Me)53 – were synthesized 
and studied in vitro and in vivo. Deletion of Asn
46
 and the substitution of Trp
47
 with 
different amino acids, together with the substitutions mentioned above, produced highly 
potent and long-acting analogues suitable for in vivo study (Figure 41). 
 
The results presented here demonstrate that both agonist activity and metabolic 
stability were important for performance of these peptides in vivo. The 
testosterone-suppressive activities of compound 56 may indicate a greater contribution 
of its improved metabolic stability, which resulted in enhanced performance of this 
metastin analogue in vivo. 
 
Continuous dosing of compound 56 at 1 nmol/h in male rats demonstrated 
testosterone suppressive efficacy as potent as that of leuprolide acetate. Leuprolide 
acetate has been known to down-regulate and desensitize the GnRH receptor, followed 
by inhibition of testosterone secretion. However, recent studies have suggested that 
KISS1R agonists may operate by a different mechanism to attenuate testosterone levels 
in the HPG axis.
70
 Compound 56 is the first short-length KISS1R agonist to possess 
testosterone suppressive activity comparable to that of leuprolide acetate in vivo. 
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Compound 56 has led to the elucidation of investigational analogues TAK-683 and 
TAK-448 (Figure 42), both of which have undergone clinical evaluation. Our results 
suggest that short-length KISS1R agonists can be efficacious in humans, leading to 
development of novel and effective investigational candidates for the therapy of 
sex-hormone-dependent diseases such as prostate cancer. 
 
This chapter includes the Accepted Manuscript version of a Published Work that 
appeared in final form in "Design, Synthesis, and Biological Evaluation of Novel 
Investigational Nonapeptide KISS1R Agonists with Testosterone-Suppressive Activity", 
Copyright © 2013, American Chemical Society after peer review and technical editing 
by the publisher. To access the final edited and published work see 
http://pubs.acs.org/doi/full/10.1021/jm401056w.
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Figure 42. Chemical structures of investigational compounds TAK-683 and TAK-448. 
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Chapter 5 Concluding Remarks 
 
In this study compound 56 with highly potent agonist activity and biological stability 
was successfully designed and synthesized from a lead peptide metastin(45-54) (Figure 
43). 
 
N-terminal truncated human metastin(45-54), Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu- 
Arg-Phe-NH2, has 3 to 10 times more potent KISS1R agonist activity than metastin. 
Although short-length analogues of metastin have the potential to possess therapeutic 
properties, their susceptibility to enzyme cleavage limits their utility. Actually 
metastin(45-54) was rapidly metabolized in mouse serum, and the half-life was less than 
1 min mainly due to sensitive Tyr and Arg residues. 
 
The metabolites formed during the incubation in serum were identified by 
HPLC-ESI-MS coupling experiments; major cleavage sites were Tyr
45
-Asn
46
 and 
Arg
53
-Phe
54
. Arg-containing peptides are known to be good substrates for trypsin-like 
proteases; therefore, we designed and synthesized a series of short-length KISS1R 
agonists to examine their agonist activity and trypsin resistance. Among analogues with 
substitutions of arginine at position 53, N
ω
-methylarginine analogue 8 showed 3-fold 
more potent agonist activity compared with metastin(45-54). Furthermore, analogue 8 
was shown to resist trypsin cleavage between positions 53 and 54. This substitution may 
be useful in the development of other Arg-containing peptides for which the avoidance 
of cleavage is desired (Chapter 2).
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There remained a great demand for more stable analogues with other amino acid 
replacements at fragile sites to improve their pharmacological properties by maintaining 
or improving agonist activity and serum stability. Incorporation of D-Tyr at position 45 
showed acceptable activity and avoided N-terminal degradation. Mouse plasma stability 
experiments showed that [D-Tyr
45
,Arg(Me)
53
]metastin(45-54) 22 was apparently 
resistant to proteolysis after a 1 h incubation in mouse serum, even though several 
metabolites were observed in the ESI-MS spectra including metastin(45-47), (45-50), 
(45-51), and (48-54), possibly due to cleavage by chymotrypsin-like proteases, NEP, 
and MMP-9. We hypothesized that more potent and long-acting analogues could be 
developed if other degradative pathways were successfully inhibited by specific 
replacement at positions 47, 48, 50, and 51. 
 
To examine this hypothesis, we first synthesized a series of analogues with 
substitution of residues at positions 50 and 51. Preliminary data (not shown) suggested 
that amino acid substitutions at Phe
50
 and Gly
51
 preserved receptor recognition. 
Therefore, we designed and synthesized amide bond isosteres and aza amino acid 
additions between positions 50 and 51 without altering their side chain moieties. This 
was expected to improve agonist activity and avoid enzymatic degradation by changing 
the overall conformation of compound 22. Replacement of Gly with azaGly in which 
the α-carbon is replaced with a nitrogen atom at position 51 improved the stability of 
amide bonds between Phe
50
-Gly
51
 and Gly
51
-Leu
52
 as determined by in vitro mouse 
serum stability studies. 
 
Substitution for tryptophan at position 47 with other amino acids produced analogues 
that were highly stable in mouse serum. D-Trp
47
 analogue 34 showed not only high 
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metabolic stability but also excellent KISS1R agonist activity (Chapter 3). 
 
Further amino acid replacements at positions 45-47 led to enhancement of KISS1R 
agonist activity and metabolic stability. N-Terminal truncation resulted in a stable 
nonapeptide, [D-Tyr
46
,D-Pya(4)
47
,azaGly
51
,Arg(Me)
53
]metastin(46-54), compound 56, 
which displayed KISS1R binding affinities comparable to metastin(45-54) and had 
improved serum stability. 
 
Continuous dosing of compound 56 demonstrated testosterone suppressive efficacy 
as potent as that of leuprolide acetate in male rats. Leuprolide acetate has been known to 
down-regulate and desensitize the GnRH receptor, followed by inhibition of 
testosterone secretion. However, recent studies have suggested that KISS1R agonists 
may operate by a different mechanism to attenuate testosterone levels in the HPG axis 
(Figure 44). 
 
In physiologically stable conditions, GnRH pulses are generated from GnRH neural 
terminals, to which kisspeptin/neurokinin B/dynorphin (KNDy) neurons presumably 
project. Kisspeptin/metastin is pulsatilely released from KNDy neurons, which 
stimulate the pituitary eventually via pulsatile GnRH secretion. GnRH neural activity 
may be also supported by kisspeptin independent other neurons. When blocking 
KISS1R on GnRH neural terminals by KISS1R antagonist, GnRH release is attenuated; 
however, further studies of KISS1R antagonist would be needed to clarify the effect on 
kisspeptin independent neural inputs.
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Acute administration of KISS1R agonist stimulates GnRH release, followed by 
abrupt elevation of plasma LH levels. On the other hand, continuous dosing of KISS1R 
agonist suppresses GnRH release paradoxically, which inhibits LH secretion. It is 
potentially because of desensitization of KISS1R on GnRH neurons. Subsequent studies 
on KISS1R agonist analogues in male rats have also suggested low-level and 
nonpulsatile leakage of GnRH, which have not been well elucidated only by use of 
metastin(45-54) with native amino acid sequence. 
 
Compound 56 is the first short-length KISS1R agonist to possess testosterone 
suppressive activity comparable to that of leuprolide acetate in vivo and has led to the 
elucidation of investigational analogues TAK-683 and TAK-448, both of which have 
undergone clinical evaluation. 
 
The results in this study suggest that short-length KISS1R agonists can be efficacious 
in humans, leading to development of novel and effective investigational candidates for 
the therapy of sex-hormone-dependent diseases such as prostate cancer (Chapter 4). 
 
Moreover, in this study biologically stable peptide analogue of endogenous ligand is 
indicated to be a powerful weapon to elucidate functions of orphan GPCRs with peptide 
ligands. This study suggests one of the most plausible and general strategy of the drug 
discovery and development targeting orphan GPCRs. 
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Chapter 6 Experimental Procedures 
 
6.1. Instruments and Materials. 
Peptide synthesis was carried out with an ABI 433A and/or manual shaker using 
Fmoc chemistry. N
α
-Fmoc-Rink amide MBHA resin was purchased from 
Calbiochem-Novabiochem Japan, Ltd (Tokyo, Japan) and Watanabe Chemical 
Industries, Ltd. (Hiroshima, Japan). PAL resin was purchased from Advanced Chemtech 
(Louisville, KY, USA). N
α
-Fmoc-(and side chain) protected amino acids were obtained 
from Peptide Institute, Inc. (Osaka, Japan), Kokusan Chemical Co., Ltd (Tokyo, Japan), 
Watanabe Chemical Industries, and Calbiochem-Novabiochem Japan. Side-chain 
protections were as follows: Arg(Pbf), Asn(Trt), Orn(Mtt), Ser(t-Bu), Thr(t-Bu), 
Tyr(t-Bu), Trp(Boc). Solvents and other reagents were reagent grade and used without 
further purification unless otherwise noted. DIPCDI, HOBt, and TFA were purchased 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Peperidine, PyBOP, PyBrop, 
and TIS were purchased from Watanabe Chemical Industries. (7-Azabenzotriazol-1-yl 
oxy)tris(pyrrolidino) phosphonium-hexafluorophosphate (PyAOP) was purchased from 
PerSeptive Biosystems Inc. (Hamburg, Germany). The substitution of the resins was 
determined by spectrophotometric analysis (Shimadzu UV-160A UV/vis 
spectrophotometer) at 290 nm of the dibenzofulvene-piperidine adduct formed upon 
deprotection of the amino terminal Fmoc group. 
 
The crude peptides were purified to homogeneity by RP-HPLC. HPLC conditions: 
YMC C18 column (20 × 150 mm), YMC C18 column (20 × 250 mm) or YMC C18 
column (30 × 250 mm); solvent gradient, A ,0.1% TFA in water; B, 0.1% TFA in 
acetonitrile with gradient indicated below; flow rate, 8 mL/min for C18 column (20 × 
99
150 mm, 20 × 250 mm), 20 mL/min for C18 column (30 × 250 mm); UV detector, 
220/254 nm. 
 
The purity of products was characterized by analytical HPLC. Reversed phase HPLC 
analyses were performed with a Shimadzu gradient system using MERCK Chromolith
®
 
FastGradient RP-18 endcapped column (2.0 × 50 mm). Prior to injection, 1 mM DMSO 
solution of each peptide was diluted with water to give a 100 μM solution; 10 μL of 
each solution was injected into the HPLC system. For reversed phase HPLC analyses, 
all peptides were eluted with a linear gradient 0–50% acetonitrile in water containing 
0.1% TFA at a flow rate 0.5 mL/min and purity was > 90% at the wavelength of 210 or 
220 nm. Molecular weights of the peptides were confirmed by MALDI-TOF MS on a 
Voyager DE-PRO system (Applied Biosystems, Foster City, CA, USA). 
 
6.2. General Procedures for Synthesis of Metastin Analogues. 
All peptides were synthesized by standard Fmoc-based solid phase synthetic methods. 
Obtained crude peptides were purified to homogeneity with preparative HPLC. The 
purity of each peptide was ascertained by analytical HPLC, and the structure assignment 
was performed by MALDI-TOF MS. Structures, HPLC retention times, and 
MALDI-TOF MS data for each peptide are shown in Tables 15-21. Determined masses 
were in full agreement with calculated masses. The general procedure is described 
below as the synthesis of [Arg(Me)
53
]metastin(45-54) compound 8 and 
[azaGly
51
]metastin(45-54) compound 36. 
 
As for compound 8, in 20 mL of dry DMF, 360 mg of 60% NaH in oil was dissolved 
and 10 mL of dry DMF solution of 2793 mg of N,N'-Bis-Boc-1-guanylpyrazole was 
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added to the solution at 0 C. The mixture was stirred for 10 minutes. Then, 748 L of 
methyl iodide was added to the mixture, followed by stirring at room temperature for 24 
hours. After the solvent was removed by distillation, the residue was dissolved in 
AcOEt, and washed with satd. NaHCO3 aq. solution and then with satd. NaCl aq. 
solution. After drying over Na2SO4, the solvent was concentrated. Purification by flash 
column chromatography gave 2.96 g of N-methyl-N,N'-bis-Boc-1-guanylpyrazole (yield 
91%). Using 480 mg of Fmoc-Phe-Rink Amide MBHA resin, which was prepared by 
introducing Fmoc-Phe into Rink Amide MBHA resin commercially available, the 
peptide chain was extended on ABI 433A to give 1080 mg of 
Boc-Tyr(t-Bu)Asn(Trt)Trp(Boc)Asn(Trt)Ser(t-Bu)PheGlyLeuOrn(Mtt)Phe-Rink Amide 
MBHA resin. To 540 mg of the peptide, 10 mL of TFA/TIS/DCM (1/5/94) was added 
and the mixture was shaken for 50 minutes. The resin was washed and then dried. After 
2 mL of DMF, 49 mg of N-methyl-N,N'-bis-Boc-1-guanylpyrazole and 87 µL of DIEA 
were added to 2/5 volume of the resin, the mixture was shaken for 15 hours to give 220 
mg of 
Boc-Tyr(t-Bu)Asn(Trt)Trp(Boc)Asn(Trt)Ser(t-Bu)PheGlyLeuArg(Boc2,Me)Phe-Rink 
Amide MBHA resin. To 50 mg of the peptide, 1 mL of 
TFA/thioanisole/m-cresol/TIS/EDT (85/5/5/2.5/2.5) was added and the mixture was 
stirred for 2 hours. Diethyl ether was added to the reaction solution, the resulting 
precipitate was centrifuged and the supernatant was removed. This procedure was 
repeated for washing. The residue was extracted with an aqueous acetic acid solution 
and the extract was filtered to remove the resin. Then, linear density gradient elution (30 
minutes) was performed with eluants A/B: 74/26-64/36 using: 0.1% TFA in water and 
eluant B: 0.1% TFA-containing acetonitrile on preparative HPLC using YMC 
D-ODS-5-ST S-5 120A column (20 × 150 mm). The fractions containing the product 
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were collected and lyophilized to give 10.5 mg of white powders; mass spectrum: 
(M+H)
+
 1316.84 (Calcd. 1316.65). Elution time on RP-HPLC: 9.12 min. 
 
Elution conditions: MERCK Chromolith
®
 FastGradient RP-18 endcapped column (2.0 
× 50 mm), linear density gradient elution with eluents A/B = 100/0-50/50 (10 min), 
using 0.1% TFA in water as eluent A and 0.1% TFA-containing acetonitrile as eluant B; 
flow rate: 0.5 mL/min. 
 
With regard to compound 36, using 321 mg of Fmoc-Phe-PAL resin, which was 
prepared by the introduction of Fmoc-Phe into PAL resin, the peptide chain was 
elongated and 80 mg of Fmoc-LeuArg(Pbf)Phe-PAL resin thus extended was subjected 
to Fmoc deprotection. After 2 mL of THF and 16 mg of CDI were added, the mixture 
was shaken for 2 hours. Then 6 µL of hydrazine monohydrate was added to the mixture. 
The mixture was shaken for an hour and the resin was then washed. After 39 mg of 
Fmoc-Phe, 93 mg of PyBrop, 27 mg of HOAt and 105 µL of DIEA were added to the 
mixture, followed by shaking for 2 hours. The resin was washed and the peptide chain 
was extended to give Boc-Tyr(t-Bu)Asn(Trt)Trp(Boc)Asn(Trt)Ser(t-Bu)Phe 
azaGlyLeuArg(Pbf)Phe-PAL resin. To 25 mg of the resin, 1 mL of 
TFA/thioanisole/m-cresol/TIS/EDT (85/5/5/2.5/2.5) was added, and the mixture was 
shaken for 2 hours. Diethyl ether was added to the reaction solution, the resulting 
precipitate was centrifuged and the supernatant was removed. This procedure was 
repeated for washing. The residue was extracted with an aqueous acetic acid solution 
and the extract was filtered to remove the resin. Linear density gradient elution (30 
minutes) was performed with eluents A/B: 74/26-64/36 using: 0.1% TFA in water and 
eluent B: 0.1% TFA-containing acetonitrile on preparative HPLC using YMC 
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D-ODS-5-ST S-5 120A column (200 × 150 mm). The fractions containing the product 
were collected and lyophilized to give 5.5 mg of white powders; mass spectrum: 
(M+H)
+
 1303.79 (Calcd. 1303.63). Elution time on RP-HPLC: 7.91 min. 
 
Elution conditions: MERCK Chromolith
®
 FastGradient RP-18 endcapped column (2.0 
× 50 mm), linear density gradient elution with eluents A/B = 100/0-50/50 (10 min), 
using 0.1% TFA in water as eluent A and 0.1% TFA-containing acetonitrile as eluent B; 
flow rate: 0.5 mL/min. 
 
6.3. Calcium Mobilization Assay. 
Intracellular calcium flux was measured as the increase in fluorescence emitted by the 
calcium-binding fluorophore using the fluo-4 NW calcium kit (Life Technologies Japan, 
Tokyo, Japan). Human KISS1R-transfected CHO cells were seeded into 96-well cell 
plates (Corning International, Tokyo, Japan) at 15,000 cells/well and cultured for an 24 
h until used in the functional calcium mobilization assays. Wells were then loaded with 
100 μL of HANKS/HBSS-4 mM probenecid-0.1% BSA sample buffer containing 
Fluo-4 Direct calcium assay reagent solution (Life Technologies Japan, Tokyo, Japan) 
for 30 minutes at 37 °C (5% CO2) and 30 minutes at room temperature. Compounds 
were dissolved in DMSO as 10 μM stock solutions and diluted appropriately with the 
sample buffer in 96-well sample plates (V-Bottom plate type 3363, Corning 
International, Tokyo, Japan). The CellLux-Cellular Fluorescence Workstation 
(PerkinElmer, MA, USA) was programmed to transfer 50 μL from each well of the 
sample plate to each well of the cell plate and to record fluorescence for 2 min, in 2 s 
intervals. Peak fluorescence counts were used to determine agonist activity. The 
instrument software normalized the fluorescent reading to give equivalent initial 
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readings at time zero. 
 
6.4. Mouse Serum Stability Test. 
Mouse blood was supplied in-house and a serum pool was prepared. Mouse serum 
was obtained after incubation at 37 C for 10 min followed by centrifugation at 13,000 
rpm at room temperature for 10 min. Aliquots were stored frozen at –80 C and thawed 
just before use. Three independent experiments were carried out for each analogue. In 
each experiment, a 45 μL mouse serum aliquot was spiked with 5 μL of 1 mM aq. 
solution of a given metastin analogue. The mixtures were incubated at 37 C for up to 4 
h, depending on the experiment. Metastin analogue/serum aliquots of 50 μL were taken 
at time 0 and at various time intervals, and quenched immediately by boiling for 3 min. 
The amount of peptide in serum extracts was determined from the area under HPLC 
peaks. The percent of a given metastin analogue recovered from serum after incubation 
at 37 C (stability index) was calculated relative to the amount of peptide extracted from 
serum at time 0 taken as 100%.  
 
6.5. Assay for Cell Growth Inhibition Activity in hKISS1R-expressed CHO Cells. 
Human KISS1R-expressing CHO cells (hKISS1R) were cultured in DMEM 
supplemented with 10% dialyzed FBS (10% dFBS/DMEM), which was used for the 
following assay. hKISS1R cells were suspended in 10% dFBS/DMEM at 10,000 
cells/mL. The cells were plated in a 96-well plate at 100 µL/well (1,000 cells/well), 
followed by culturing overnight at 37 C in a 5% CO2 incubator. On the following day, 
the medium was removed and 90 µL of 10% dFBS/DMEM supplemented with 0.5% 
BSA (0.5% BSA/10% dFBS/DMEM) was added. Subsequently, 10 µL of a solution of 
metastin or a metastin derivative in 0.5% BSA/10% dFBS/DMEM was added to each 
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well, followed by culturing at 37 C in a 5% CO2 incubator for 3 days. After 10 µL of 
Cell Counting Kit-8 solution (Dojin Chemical Laboratory, Kumamoto, Japan) was 
added to each well, incubation was performed at 37C in a 5% CO2 incubator for 4 h 
and absorbance was measured at 450 nm. 
 
6.6. Induction of Ovulation in Immature Rats Using Metastin Derivatives. 
eCG and hCG (serotropin and gonatropin, respectively, Asuka Pharmaceutical Co. 
Ltd., Tokyo, Japan) were dissolved in saline (Otsuka Pharmaceutical Factory, Inc., 
Tokushima, Japan) at 100 IU/mL. Using a 1 mL tuberculin syringe with a 26-gauge 
needle (Terumo Co. Ltd, Tokyo, Japan), eCG was subcutaneously injected into the 
dorsal area of 23-day-old female Wistar rats between 9:00 and 10:00 AM (Charles River 
Japan, Inc., Kanagawa, Japan) at a dose of 10 IU/animal. Two days after the eCG 
injection, test agents were dissolved in saline and injected dorsally into 5 rats/group 
(control = 6 rats) as follows: Group A: 10 IU hCG (0.1 mL); Group B: 100 nmol/kg 
human metastin; Group C: 100 nmol/kg compound 56; Group D: 30 nmol/kg compound 
56; Group E: Saline. 
 
Following administration of the investigational agents, each animal was sacrificed by 
decapitation after 24–25 h to recover blood, bilateral oviducts, and uterus. Blood was 
collected into tubes containing aprotinin solution (Trasylol; Bayer HealthCare 
Pharmaceuticals, Leverkusen, Germany) and EDTA to prevent clotting, and centrifuged 
at 2000 G for 25 min to obtain plasma. 
 
The number of oöcytes was counted as previously described.
5
 Where retained oöcytes 
in the oviducal ampulla were confirmed by stereomicroscopy, the ampulla was 
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punctured with a 27-gauge syringe needle (Terumo) to retrieve the oöcytes. After 
granulosa cells surrounding the oöcytes were removed by trypsin treatment, the number 
of oöcytes was counted. Where the retained oöcytes in the oviductal ampulla were not 
confirmed by stereomicroscopy, a 27-gauge needle with a polished tip was inserted into 
the tubal ostium and more than 400 µL of saline was flushed into the oviduct and uterus 
and the presence or absence of oöcytes in the effluent was determined. 
 
6.7. Evaluation of the Effects of Metastin Peptide Derivatives on Blood 
Testosterone Levels in Mature Male Rats. 
A metastin peptide derivative was dissolved in distilled water (Otsuka Joryusui K.K.) 
and loaded into 5 ALZET
®
 osmotic pumps (2 mM in 0.2 mL, release rate: 0.001 mL/h, 
Model 2001, DURECT Corporation, Cupertino, CA, USA). Each filled ALZET
®
 pump 
was implanted subcutaneously into the dorsal region of 9-week old male CD(SD)IGS or 
Copenhagen rats (5 rats/group; Charles River Japan, Inc.) under ether anesthesia. For 
negative controls, distilled water (Otsuka Pharmaceutical Co., Ltd) was loaded in 5 
ALZET
®
 osmotic pumps, which were similarly implanted. These pump-implanted rats 
were fed for 6 days under normal feeding conditions. After weighing, animals were 
decapitated to collect blood in tubes containing aprotinin and EDTA 2Na to recover 
plasma as described above. From the obtained plasma, 0.05 mL was applied to RIA 
(DPC. Total Testosterone Kit, Siemens Healthcare Diagnostics Inc., Deerfield, IL) to 
measure the plasma testosterone level of each rat. The value below the limit of detection 
(0.04 ng/mL ) in RIA was treated as 0.04 and results were expressed as percent of 
control value. 
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